Matthias Guckenberger
Chairman
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (24)
IntroductionAssessments of local control (LC) following stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) play a crucial role in evaluating treatment efficacy. However, there is significant variability in how LC is defined and assessed across studies, making it challenging to compare outcomes and establish standardized benchmarks. This heterogeneity impacts clinical decision-making, prognostic assessment, and the interpretation of lung SBRT efficacy in both research and clinical practice.MethodsA systematic review was conducted following PRISMA guidelines to identify criteria used in reporting post-SBRT local control (LC) rates. A comprehensive PubMed search identified studies published between 2006 and 2023 reporting LC or primary tumor control rates following SBRT for early-stage NSCLC. Eligible studies were independently reviewed, and LC definitions were categorized based on the anatomical sites considered and the criteria used to define relapse.ResultsOf 155 studies identified, 113 met the inclusion criteria. LC determinations were described as ‘local control’, ‘local failure’, ‘local recurrence’, or ‘primary tumor control’ in 39%, 32%, 24%, and 4% of studies, respectively. Anatomic sites assessed for LC included recurrence within the primary tumor site, same lobe, ipsilateral lung, and regional nodes in 68%, 11%, 4%, and 2%, respectively; 15% did not specify anatomical location. We identified 12 different criteria for LC and PTC evaluations, including requirements for a specific imaging modality (CT or PET), growth threshold (RECIST or up to 50% increase), minimum growth duration (2-36 months or serial changes), or histopathological confirmation in 28%, 31%, 18%, and 1%, respectively. LC rates included recurrence events occurring outside of the primary tumor site in 32% of publications.ConclusionsTo improve consistency and interpretability of SBRT outcomes, LC should be reported using standardized, treatment-site specific criteria. We recommend that LC be restricted to recurrence at the treatment-site, explicitly excluding same-lobe, ipsilateral lung, and nodal failures, which should be reported as separate endpoints. LC assessments should specify the imaging modality used, apply objective growth thresholds based on serial imaging rather than single time-point changes, and clearly define minimum duration for progression. Adoption of uniform terminology and anatomically precise definitions across studies is essential to enable valid cross-trial comparisons, support reliable meta-analyses, and ensure that SBRT efficacy is accurately represented in clinical guidelines and patient counseling.
Year:
2026
Aim: An Early-Stage Non-Small Cell Lung Cancer (ES-NSCLC) patient candidate for stereotactic body radiotherapy (SBRT) may start their treatment without a histopathological assessment, due to relevant comorbidities. The aim of this study is twofold: (i) build prognostic models to test the association between CT-derived radiomic features (RFs) and the outcomes of interest (overall survival (OS), progression-free survival (PFS) and loco-regional progression-free survival (LRPFS)); (ii) quantify whether the combination of clinical and radiomic descriptors yields better prediction than clinical descriptors alone in prognostic modeling for ES-NSCLC patients treated with SBRT. Methods: Simulation CT scans of ES-NSCLC patients treated with curative-intent SBRT at the European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy between 2013 and 2023 were retrospectively retrieved. PyRadiomics v3.0.1 was used for image preprocessing and subsequent RFs extraction and selection. A radiomic score was calculated for each patient, and three prognostic models (clinical model, radiomic model, clinical-radiomic model) for each survival endpoint were built. Relative performances were compared using the C-index. All analyses were considered statistically significant if p < 0.05. The statistical analyses were performed using R Software version 4.1. Results: A total of 100 patients met the inclusion criteria. Median age at diagnosis was 76 (IQR: 70–82) years, with a median Charlson Comorbidity Index (CCI) of 7 (IQR: 6–8). At the last available follow-up, 76 patients were free of disease, 17 were alive with disease, and 7 were deceased. Considering relapses, progression of any kind was diagnosed in 31 cases. Regarding model performances, the radiomic score allowed for excellent prognostic discrimination for all the considered endpoints. Of note, the use of RFs alone proved to be more informative than clinical characteristics alone for the prediction of both OS and LRPFS, but not for PFS, for which the individual predictive performances slightly favored the clinical model. Conclusion: The use of RFs for outcome prediction in this clinical setting is promising, and results seem to be rather consistent across studies, despite some methodological differences that should be acknowledged. Further studies are being planned in our group to externally validate these findings, and to better determine the potential of RFs as non-invasive and reproducible biomarkers in ES-NSCLC.
Year:
2025
Background Definitive (chemo)radiotherapy of oropharyngeal squamous cell carcinoma (SCC) consists of treatment of the macroscopic tumor and prophylactic irradiation of large parts of the lymphatic drainage system: the elective clinical target volume (CTV). There is limited data and quantification of (occult) lymphatic spread and the required extent of the elective CTV. De-escalation of the irradiated volume could result in less early and late toxicity and less affection of the immune system. In this study, we reduce the elective CTV based on the personalized factors T-stage, clinical lymphatic involvement, and lateralization of the primary tumor. Methods The primary objective is to evaluate the efficacy and safety of an individualized de-escalation of elective node irradiation volumes. We collected a multi-institutional dataset of 598 oropharyngeal SCC patients in whom detailed lymph node involvement was reported. The data can be explored on the publicly available online platform LyProX.org. Based on the data, we developed a model of lymphatic tumor progression to estimate the probability of occult metastases in the clinically negative lymph node levels (LNLs). Metastatic lymphatic progression is described via a hidden Markov model. The patient’s state of lymph node involvement is described by hidden binary random variables, and the transition matrix describes the probabilities of lymphatic spread. Based on this model and clinical judgement, we created tables that define the personalized elective CTV for different combinations of T-stage, midline extension and clinical LNL involvement. The elective CTV is defined such that the cumulative risk of occult metastases in all non-irradiated LNLs is below 10%. The primary endpoint of this multicentric, prospective, single-arm trial is the rate of out-of-field nodal recurrences after 2 years. The study will be conducted in 6 centers across Switzerland and 120 patients will be enrolled. Discussion This study sets out to personalize the elective CTV in oropharyngeal SCC patients, with the goal to de-escalate radiotherapy for patients and herewith improve therapy-associated toxicity and quality of life. The results of this study may be used to personalize treatment in oropharyngeal SCC patients. Trial Registration This study sets out to personalize the elective CTV in oropharyngeal SCC patients, with the goal to de-escalate radiotherapy for patients and herewith improve therapy-associated toxicity and quality of life. The results of this study may be used to personalize treatment in oropharyngeal SCC patients.
Year:
2025
PURPOSE Oncology has experienced substantial growth in clinical trial activity over the past two decades, but a comprehensive evaluation of radiation oncology research is lacking. This study analyzed trends in radiation therapy trials using data from ClinicalTrials.gov. MATERIALS AND METHODS A comprehensive analysis was conducted on 4,253 radiation oncology trials registered in the database. Key outcomes examined included trends in trial activity over time, the geographic distribution of trials, and the phases of clinical trials conducted. RESULTS Clinical trial activity in radiation oncology has increased significantly, with 4,253 trials registered by February 2024. Digestive, CNS, and head and neck cancers accounted for 49.7% of studies. Research on oligometastasis emerged in the past decade (2.2%), while hematology trials declined (9.7%). Phase II trials dominated (51.3%), with most originating in North America (58.2%). Europe (21.2%) and Asia (25.2%) have shown increasing contributions, reflecting a global shift. Only 6% of trials received industry funding, highlighting the financial challenges in the field. CONCLUSION These findings underscore the dynamic nature of radiation oncology research and the need to address regional disparities, advance novel technologies and drug-radiotherapy combinations through phase I and III trials, and increase industry investment.
Year:
2025
Year:
2024
Year:
2024
Introduction Despite radical prostatectomy (RP) and radiotherapy (RT) being established treatments for localised prostate cancer, a significant number of patients experience recurrent disease. While conventionally fractionated RT is still being used as a standard treatment in the postoperative setting, ultra-hypofractionated RT has emerged as a viable option with encouraging results in patients with localised disease in the primary setting. In addition, recent technological advancements in RT delivery and precise definition of isolated macroscopic recurrence within the prostate bed using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multiparametric MRI (mpMRI) allow the exploration of ultra-hypofractionated schedules in the salvage setting using five fractions. Methods and analysis In this single-arm prospective phase II multicentre trial, 36 patients with node-negative prostate adenocarcinoma treated with RP at least 6 months before trial registration, tumour stage pT2a–3b, R0–1, pN0 or cN0 according to the UICC TNM 2009 and evidence of measurable local recurrence within the prostate bed detected by PSMA PET/CT and mpMRI within the last 3 months, will be included. The patients will undergo focal ultra-hypofractionated salvage RT with 34 Gy in five fractions every other day to the site of local recurrence in combination with 6 months of androgen deprivation therapy. The primary outcome of this study is biochemical relapse-free survival at 2 years. Secondary outcomes include acute side effects (until 90 days after the end of RT) of grade 3 or higher based on Common Terminology Criteria for Adverse Events V.5, progression-free survival, metastasis-free survival, late side effects and the quality of life (based on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30, QLQ-PR25). Ethics and dissemination The study has received ethical approval from the Ethics Commission of the Canton of Bern (KEK-BE 2022-01026). Academic dissemination will occur through publications and conference presentations. Trial registration number NCT05746806 .
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Collaborators (35)
David A. Palma
Western University
Jesper Grau Eriksen
Professor
Aarhus Universitetshospital
Lotte Wilke
Dept. Head of Medical Physics
University Hospital of Zurich
Helena Verkooijen
Head of Imaging Division (departments of Radiology, Radiotherapy, Nuclear Medicine and Clinical Physics)
The Netherlands Cancer Institute
Stefanie Hayoz
Head of Statistics
-
Ali Afshar-Oromieh
University Hospital of Bern
Monica Casiraghi
Thoracic Surgeon
European Institute of Oncology
Jeffrey D. Bradley
Professor and Vice Chair
Hospital of the University of Pennsylvania
Mohamed Shelan
Associate Professor
-
Sandrine Katsahian
Université Paris Cité
Stefano Fanti
ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA
Panagiotis Balermpas
University Hospital of Zurich
Nicolaus Andratschke
Deputy chair
University Hospital of Zurich
Francesco Ceci
Assistant Professor
University of Milan
Shankar Siva
University of Melbourne
Marco M. E. Vogel
Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit
Hanna Rahbek Mortensen
Associate Professor
Aarhus University
Justus Domschikowski
Head of Department
Malteser Krankenhaus St. Franziskus Hospital Flensburg
Alessio Giuseppe Morganti
ALMA MATER STUDIORUM UNIVERSITY OF BOLOGNA
Suresh Senan
Professor of clinical experimental radiotherapy
Amsterdam University Medical Centers
Sara Gandini
Group Leader T, PhD
European Institute of Oncology
Thomas Geiser
Chairman
University of Bern
Bertrand Pouymayou
University Hospital of Zurich
Federico Mastroleo
Mayo Clinic
Jan Unkelbach
Associate Professor for Medical Physics
University of Zurich
Pietro Mancosu
Docenti di ruolo di IIa fascia
Humanitas University
Sofie Ceberg
Associated Professor/ University lecturer
Lund University
Sue S. Yom
University of California, San Francisco
Francesca Serani
Ricercatori a tempo determinato
University of Padova
Per Munck af Rosenschold
Lund University
Stephanie Elisabeth Combs
Professor and Chair
Technical University of Munich (TUM)
Christina T Muijs
Associate professor
University Medical Center Groningen
Carmen Stromberger
Head of Department
Vivantes Klinikum
Per Pfeiffer
University of Southern Denmark
Umberto Ricardi
University of Turin
Make your next move.
Prepare your application
Review drafts before you send them.